Amylin at the interface between metabolic and neurodegenerative disorders

Frontiers in Neuroscience

Volumn 9, Issue MAY, 2015, Pages

  Lutz, Thomas A ^a   Meyer, Urs ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Alzheimer's disease (AD); Amylin; Dementia; Hyperglycemia; Insulin; Obesity; Type 2 diabetes; amyloid

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; AMYLIN RECEPTOR; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCITONIN[8-32][30 ASPARAGINE 32 TYROSINAMIDE]; CHOLECYSTOKININ; INSULIN; LEPTIN; PRAMLINTIDE;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DRUG MECHANISM; ENERGY EXPENDITURE; FOOD INTAKE; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN SYNTHESIS; SATIETY;

EID: 84930634209     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00216     Document Type: Article

References (147)

1. Adler, B.L., Yarchoan, M., Hwang, H.M., Louneva, N., Blair, J.A., Palm, R., Smith, M.A., Lee, H.G., Arnold, S.E., Casadesus, G. (2014). Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol. Aging. 35, 793-801.
2. Arnelo U., Permert, J., Adrian, T.E., Larsson, J., Westermark, P., Reidelberger, R.D. (1996). Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am. J. Physiol. 271, R1654-1659.
3. Bailey, R.J., Walker, C.S., Ferner, A.H., Loomes, K.M., Prijic, G., Halim, A., Whiting, L., Phillips, A.R., Hay, D.L. (2012). Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes. Br. J. Pharmacol. 166: 151-167.
4. Baisley S.K., Baldo, B.A. (2014). Amylin receptor signaling in the nucleus accumbens negatively modulates μ-opioid-driven feeding. Neuropsychopharmacol. 39, 3009-3017.
5. Banks, W.A., Kastin, A.J. (1998). Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides. 19, 883-889.
6. Baranello, R.J., Bharani, K.L., Padmaraju, V., Chopra, N., Lahiri, D.K., Greig, N.H., Pappolla, M.A., Sambamurti, K. (2015). Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr. Alzheimer. Res. 12, 32-46.
7. Bassil, F., Fernagut, P.O., Bezard, E., Meissner, W.G. (2014). Insulin, IGF- 1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog. Neurobiol. 118, 1-18.
8. Bennett, R.G., Hamel, F.G., Duckworth, W.C. (2003). An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes. 52, 2315-2320.
9. Berridge, K.C., Robinson, T.E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev. 28, 309-369.
10. Betsholtz, C., Christmansson, L., Engström, U., Rorsman, F., Svensson, V., Johnson, K.H., Westermark, P. (1989). Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett. 251, 261-264.
11. Bhavsar, S., Watkins, J., Young, A. (1998). Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol. Behav. 64, 557-561.
12. Boyle, C.N., Lutz, T.A. (2011). Amylinergic control of food intake in lean and obese rodents. Physiol. Behav. 105, 129-137.
13. Boyle, C.N., Rossier, M.M., Lutz, T.A. (2011). Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Physiol. Behav. 104, 20-28.
14. Braegger, F.E., Asarian, L., Dahl, K., Lutz, T.A., Boyle, C.N. (2014). The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping. Eur. J. Neurosci. 40, 3055-3066.
15. Bursch, W., Ellinger, A., Gerner, C., Fröhwein, U., Schulte-Hermann, R. (2000). Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann. N. Y. Acad. Sci. 926, 1-12.
16. Butterfield, D.A., Di Domenico, F., Barone, E. (2014). Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim. Biophys. Acta. 1842, 1693-1706.
17. Chen, Z., Zhong, C. (2014). Oxidative stress in Alzheimer's disease. Neurosci. Bull. 30, 271-281.
18. Chiang, D.J., Pritchard, M.T., Nagy, L.E. (2011). Obesity, diabetes mellitus, and liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G697-702.
19. Clark, A., Nilsson, M.R. (2004). Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia. 47, 157-169.
20. Davenport, E.L., Morgan, G.J., Davies, F.E. (2008). Untangling the unfolded protein response. Cell Cycle. 7, 865-869.
21. de la Monte, S.M. (2012). Contributions of brain insulin resistance and deficiency in amyloid related neurodegeneration in Alzheimer's disease. Drugs. 72, 49-66.
22. de la Monte, S.M., Tong, M. (2014). Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 88, 548-559.
23. de la Monte, S.M., Wands, J.R. (2008). Alzheimer's disease i s type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2, 1101-1113.
24. Desai, G.S., Zheng, C., Geetha, T., Mathews, S.T., White, B.D., Huggins, K.W., Zizza, C.A., Broderick, T.L., Babu, J.R. (2014). The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. J. Alzheimers. Dis. 42, 347-356.
25. Donath, M.Y., Dalmas, É., Sauter, N.S., Böni-Schnetzler, M. (2013). Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17, 860-872.
26. Donath, M.Y., Shoelson, S.E. (2011). Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107.
27. Edvinsson, L., Goadsby, P.J., Uddman, R. (2001). Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal. 1, 168-80.
28. Edwards, G.L., Gedulin, B.R., C. J, Dilts RP, C.C. M, and Young A. (1998). Area postrem (AP)-lesions block the regulation of gastric emptying by amylin. Neurogastroenterol. Motil. 10, 26.
29. Eikelenboom, P., van Exel, E., Hoozemans, J.J., Veerhuis, R., Rozemuller, A.J., van Gool, W.A. (2010). Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener. Dis. 7, 38-41.
30. Emmerzaal, T.L., Kiliaan, A.J., Gustafson, D.R. (2015). 2003-2013: a decade of body mass index, Alzheimer's disease, and dementia. J. Alzheimers Dis. 43, 739-755.
31. Enoki, S., Mitsukawa, T., Takemura, J., Nakazato, M., Aburaya, J., Toshimori, H., Matsukara, S. (1992). Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 15, 97-102.
32. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J., Guenette, S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U S A. 100, 4162-4167.
33. Fawver, J.N., Ghiwot, Y., Koola, C., Carrera, W., Rodriguez-Rivera, J., Hernandez, C., Dineley, K.T., Kong, Y., Li, J., Jhamandas, J., Perry, G., Murray, I.V. (2014). Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer's disease. Curr. Alzheimer Res. 11, 928-940.
34. Fernandes-Santos, C., Zhang, Z., Morgan, D.A., Guo, D.F., Russo, A.F., Rahmouni, K. (2013). Amylin acts in the central nervous system to increase sympathetic nerve activity. Endocrinology 157, 2481-2488.
35. Ferrer, I. (2012). Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol. 97, 38-51.
36. Friedman, J.M. (1997). Leptin, leptin receptors and the control of body weight. Eur. J. Med. Res. 2, 7-13.
37. Fukuda, T., Hirai, Y., Maezawa, H., Kitagawa, Y., Funahashi, M. (2013). Electrophysiologically identified presynaptic mechanisms underlying amylinergic modulation of area postrema neuronal excitability in rat brain slices. Brain Res. 1494, 9-16.
38. Ginter, E., Simko, V. (2012a). Global prevalence and future of diabetes mellitus. Adv. Exp. Med. Biol. 771, 35-41.
39. Ginter, E., Simko, V. (2012b). Type 2 diabetes mellitus, pandemic in 21st century. Adv. Exp. Med. Biol. 771, 42-50.
40. Götz, J., Lim, Y.A., Eckert, A. (2013). Lessons from two prevalent amyloidoses-what amylin and Aβ have in common. Front Aging Neurosci. 5, 38.
41. Greenwood, C.E., Winocur, G. (2005). High-fat diets, insulin resistance and declining cognitive function. Neurobiol. Aging. 26 Suppl 1, 42-45.
42. Guardado-Mendoza, R., Davalli, A.M., Chavez, A.O., Hubbard, G.B., Dick, E.J., Majluf-Cruz, A., et al., (2009). Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc. Natl. Acad. Sci. U S A. 106, 13992-13997.
43. Gurlo, T., Ryazantsev, S., Huang, C.J., Yeh, M.W., Reber, H.A., Hines, O.J., O'Brien, T.D., Glabe, C.G., Butler, P.C. (2010). Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am. J. Pathol. 176, 861-869.
44. Hampel, H., Prvulovic, D., Teipel, S., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M.W., Dodel, R., Leyhe, T., Bertram, L., Hoffmann, W., Faltraco, F.; German Task Force on Alzheimer's Disease (GTF-AD) (2011). The future of Alzheimer's disease: the next 10 years. Prog. Neurobiol. 95, 718-728.
45. Hardy, J., Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297, 353-356.
46. Höppener, J.W., Lips, C.J. (2006). Role of islet amyloid in type 2 diabetes mellitus. Int. J. Biochem. Cell Biol. 38, 726-736.
47. Höppener, J.W., Oosterwijk, C., van Hulst, K.L., Verbeek, J.S., Capel, P.J., de Koning, E.J., Clark, A., Jansz, H.S., Lips, C.J. (1994). Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice. J. Cell. Biochem. 55 Suppl, 39-53.
48. Hou, X., Ling, Z., Quartier, E., Foriers, A., Schuit, F., Pipeleers, D., Van Schravendijk, C. (1999). Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia. 42, 188-194.
49. Huang, C.J., Lin, C.Y., Haataja, L., Gurlo, T., Butler, A.E., Rizza, R.A., Butler, P.C. (2007). High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 56, 2016-2027.
50. Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J., Langa, K.M. (2013). Monetary costs of dementia in the United States. N. Engl. J. Med. 368, 1326-1334.
51. Isaksson, B., Wang, F., Permert, J., Olsson, M., Fruin, B., Herrington, M.K., Enochsson, L., Erlanson-Albertsson, C., Arnelo, U. (2005). Chronically administered islet amyloid polypeptide in rats serves as an adiposity inhibitor and regulates energy homeostasis. Pancreatology 5, 29-36.
52. Jackson, K., Barisone, G.A., Diaz, E., Jin, L.W., DeCarli, C., Despa, F. (2013). Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann. Neurol. 74, 517-526.
53. Jaikaran, E.T., Clark, A. (2001). Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim. Biophys. Acta. 1537, 179-203.
54. Jaikaran, E.T., Higham, C.E., Serpell, L.C., Zurdo, J., Gross, M., Clark, A., Fraser, P.E. (2001) Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308, 515-525.
55. S., Snell, J.M., Sheftic, S.R., Patil, S.M., Daniels, S.B., Kolling, F.W., Alexandrescu, A.T. (2014). pH dependence of amylin fibrillization. Biochemistry. 53, 300-310.
56. Johnson, K.H., O'Brien, T.D., Jordan, K., Westermark, P. (1989). Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am. J. Pathol. 135, 245-250.
57. Jurgens, C.A., Toukatly, M.N., Fligner, C.L., Udayasankar, J., Subramanian, S.L., Zraika, S., Aston-Mourney, K., Carr, D.B., Westermark, P., Westermark, G.T., Kahn, S.E., Hull, R.L. (2011). β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am. J. Pathol. 178, 2632-2640.
58. Kahn, S.E., Cooper, M.E., Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 383, 1068-1083.
59. Kahn, S.E., D'Alessio, D.A., Schwartz, M.W., Fujimoto, W.Y., Ensinck, J.W., Taborsky, G.J. Jr, Porte, D. Jr. (1990). Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 39, 634-638.
60. Karran, E., Mercken, M., De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698-712.
61. Kenny, P.J. (2011). Common cellular and molecular mechanisms in obesity and drug addiction. Nat. Rev. Neurosci. 12, 638-651.
62. Kiliaan, A.J., Arnoldussen, I.A., Gustafson, D.R. (2014). Adipokines: a link between obesity and dementia? Lancet Neurol. 13, 913-923.
63. Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W.R., Vienberg, S.G., Pothos, E.N., Kahn, C.R. (2015). Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. U S A. 112, 3463-3468.
64. Leboucher, A., Laurent, C., Fernandez-Gomez, F.J., Burnouf, S., Troquier, L., Eddarkaoui, S., Demeyer, D., Caillierez, R., Zommer, N., Vallez, E., Bantubungi, K., Breton, C., Pigny, P., Buée-Scherrer, V., Staels, B., Hamdane, M., Tailleux, A., Buée, L., Blum, D. (2013). Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes. 62, 1681-1688.
65. Li, L., Hölscher, C. (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402.
66. Li, Y., Xu, W., Mu, Y., Zhang, J.Z. (2013). Acidic pH retards the fibrillization of human Islet Amyloid Polypeptide due to electrostatic repulsion of histidines. J. Chem. Phys. 139, 055102.
67. Lutz, T.A. (2005). Pancreatic amylin as a centrally acting satiating hormone. Curr. Drug Targets. 6, 181-189.
68. Lutz, T.A. (2009). Control of food intake and energy expenditure by amylin-therapeutic implications. Int. J. Obes. 33 Suppl 1, S24-27.
69. Lutz, T.A. (2010). The role of amylin in the control of energy homeostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1475-1484.
70. Lutz, T.A., Althaus, J., Rossi, R., Scharrer, E. (1998a). Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am. J. Physiol. 274, R1777-1782.
71. Lutz, T.A., Del Prete, E., Scharrer, E. (1995). Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16, 457-462.
72. Lutz, T.A., Geary, N., Szabady, M.M., Del Prete, E., Scharrer, E. (1995). Amylin decreases meal size in rats. Physiol. Behav. 58, 1197-1202.
73. Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T., Scharrer, E. (2001). The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord. 25, 1005-1011.
74. Lutz, T.A., Rand, J.S. (1993). A review of new developments in type 2 diabetes in human beings and cats. Br. Vet. J. 149, 527-536.
75. Lutz, T.A., Senn, M., Althaus, J., Del Prete, E., Ehrensperger, F., Scharrer, E. (1998b). Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19, 309-317.
76. Mack, C., Wilson, J., Athanacio, J., Reynolds, J., Laugero, K., Guss, S., Vu, C., Roth, J., Parkes, D. (2007). Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1855-1863.
77. Mack, C.M., Soares, C.J., Wilson, J.K., Athanacio, J.R., Turek, V.F., Trevaskis, J.L., et al., (2010). Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int. J. Obes. 34, 385-395.
78. Marciniak, S.J., Ron, D. (2006). Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86, 1133-1149.
79. Marzban, L., Trigo-Gonzalez, G., Verchere, C.B. (2005). Processing of pro-islet amyloid polypeptide in the constitutive and regulated secretory pathways of beta cells. Mol. Endocrinol. 19, 2154-2163.
80. Marzban, L., Trigo-Gonzalez, G., Zhu, X., Rhodes, C.J., Halban, P.A., Steiner, D.F., Verchere, C.B. (2004). Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes. 53, 141-148.
81. Matveyenko AV, Butler PC. (2006). Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J. 47, 225-233.
82. McDonald, RJ. (2002). Multiple combinations of co-factors produce variants of age-related cognitive decline: a theory. Can. J. Exp. Psychol. 56, 221-239.
83. Mietlicki-Baase, E.G., Hayes, M.R. (2014). Amylin activates distributed CNS nuclei to control energy balance. Physiol. Behav. 136, 39-46.
84. Mietlicki-Baase, E.G., Reiner, D.J., Cone, J.J., Olivos, D.R., McGrath, L.E., Zimmer, D.J., Roitman, M.F., Hayes, M.R. (2015). Amylin modulates the mesolimbic dopamine system to control energy balance. Neuropsychopharmacol. 40, 372-385.
85. Mietlicki-Baase, E.G., Rupprecht, L.E., Olivos, D.R., Zimmer, D.J., Alter, M.D., Pierce, R.C., et al. (2013). Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake. Neuropsychopharmacology 38, 1685-1697.
86. Mollet, A., Gilg, S., Riediger, T., Lutz, T.A. (2004). Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol. Behav. 81, 149-155.
87. Mollet, A., Meier, S., Grabler, V., Gilg, S., Scharrer, E., Lutz, T.A. (2003). Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. Peptides 24, 91-98.
88. Morales, I., Guzmán-Martínez, L., Cerda-Troncoso, C., Farías, G.A., Maccioni, R.B. (2014). Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci. 8, 112.
89. Moriarty DF, Raleigh DP. (1999). Effects of sequential proline substitutions on amyloid formation by human amylin20-29. Biochemistry. 38, 1811-1818.
90. Morris, M.C., Tangney, C.C. (2014). Dietary fat composition and dementia risk. Neurobiol. Aging. 35 Suppl 2, S59-64.
91. Nedergaard, J., Cannon, B. (2014). The browning of white adipose tissue: some burning issues. Cell Metab. 20, 396-407.
92. Osaka, T., Tsukamoto, A., Koyama, Y., Inoue, S. (2008). Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 29, 1028-1035.
93. Oskarsson, M.E., Paulsson, J.F., Schultz, S.W., Ingelsson, M., Westermark, P., Westermark, G.T. (2015). In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am. J. Pathol. 185, 834-846.
94. Osto, M., Zini, E., Reusch, C.E., Lutz, T.A. (2013). Diabetes from humans to cats. Gen. Comp. Endocrinol. 182, 48-53.
95. Ott, A., Stolk, R.P., Hofman, A., van Harskamp, F., Grobbee, D.E., Breteler, M.M. (1996). Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 39, 1392-1397.
96. Oyadomari, S., Araki, E., Mori, M. (2002). Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis. 7, 335-345.
97. Parks, J.K., Smith, T.S., Trimmer, P.A., Bennett, J.P. Jr, Parker, W.D. Jr. (2001). Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76, 1050-1056.
98. Paulsson, J.F., Andersson, A., Westermark, P., Westermark, G.T. (2006). Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets. Diabetologia. 49, 1237-1246.
99. Paulsson, J.F., Westermark, G.T. (2005). Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 54, 2117-2125.
100. Pieber, T.R., Roitelman, J., Lee, Y., Luskey, K.L., Stein, D.T. (1994). Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am. J. Physiol. 267, E156-164.
101. Potes CS, Turek VF, Cole RL, Vu C, Roland BL, Roth JD, Riediger T, and Lutz TA. Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. Am J Physiol Regul Integr Comp Physiol 299: R623-631, 2010.
102. Preston, A.M., Gurisik, E., Bartley, C., Laybutt, D.R., Biden, T.J. (2009). Reduced endoplasmic reticulum (ER)-to-Golgi protein trafficking contributes to ER stress in lipotoxic mouse beta cells by promoting protein overload. Diabetologia. 52, 2369-2373.
103. Qiu, W.Q., Li, H., Zhu, H., Scott, T., Mwamburi, M., Rosenberg, I., Rosenzweig, J. (2014). Plasma amylin and cognition in diabetes in the absence and the presence of insulin treatment. J. Diabetes Metab. 5, pii: 458.
104. Qiu, W.Q., Zhu, H. (2014). Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease? Front. Aging Neurosci. 6, 186.
105. Reidelberger RD, Kelsey L, and Heimann D. Effects of amylin- related peptides on food intake, meal patterns, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 282: R1395-1404, 2002.
106. Reidelberger RD1, Haver AC, Arnelo U, Smith DD, Schaffert CS, Permert J. Amylin receptor blockade stimulates food intake in rats. Am J Physiol 287: R568-574, 2004.
107. Reitz, C., Brayne, C., Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137-152.
108. Reitz, C., Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 88, 640-651.
109. Riediger, T., Zuend, D., Becskei, C., Lutz, T.A. (2004). The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R114-122.
110. Ríos, J.A., Cisternas, P., Arrese, M., Barja, S., Inestrosa, N.C. (2014). Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Prog. Neurobiol. 121, 125-146.
111. Roth, J.D., Hughes, H., Kendall, E., Baron, A.D., Anderson, C.M. (2006). Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147, 5855-5864.
112. Rowland, N.E., Crews, E.C., Gentry, R.M. (1997). Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul. Pept. 71, 171-174.
113. Rushing, P.A., Hagan, M.M., Seeley, R.J., Lutz, T.A., D'Alessio, D.A., Air, E.L., Woods, S.C. (2001). Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142, 5035-5038.
114. Rushing, P.A., Seeley, R.J., Air, E.L., Lutz, T.A., Woods, S.C. (2002). Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences. Peptides 23, 985-988.
115. Scherz-Shouval, R., Elazar, Z. (2007). ROS, mitochondria and the regulation of autophagy. Trends Cell Biol. 17, 422-427.
116. Schwartz, M.W., Woods, S.C., Porte, D. Jr., Seeley, R.J., Baskin, D.G. (2000). Central nervous system control of food intake. Nature 404, 661-671.
117. Schwartz, M.W., Woods, S.C., Seeley, R.J., Barsh, G.S., Baskin, D.G., Leibel, R.L. (2003). Is the energy homeostasis system inherently biased toward weight gain? Diabetes 52, 232-238.
118. Sebastião, I., Candeias, E., Santos, M.S., de Oliveira, C.R., Moreira, P.I., Duarte, A.I. (2014). Insulin as a bridge between type 2 diabetes and Alzheimer disease - How anti-diabetics could be a solution for dementia. Front. Endocrinol. 5, 110.
119. Seeman, P., Seeman, N. (2011). Alzheimer's disease: β-amyloid plaque formation in human brain. Synapse. 65, 1289-1297.
120. Sexton, P.M., Paxinos, G., Kenney, M.A., Wookey, P.J., Beaumont, K. (1994). In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62, 553-567.
121. Srodulski, S., Sharma, S., Bachstetter, A.B., Brelsfoard, J.M., Pascual, C., Xie, X.S., Saatman, K.E., Van Eldik, L.J., Despa, F. (2014). Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol. Neurodegener. 9, 30.
122. Steneberg, P., Bernardo, L., Edfalk, S., Lundberg, L., Backlund, F., Ostenson, C.G., Edlund, H. (2013). The type 2 diabetes-associated gene ide is required for insulin secretion and suppression of α-synuclein levels in β-cells. Diabetes. 62, 2004-2014.
123. Stienstra R., Haim, Y., Riahi, Y., Netea, M., Rudich, A., Leibowitz, G. (2014). Autophagy in adipose tissue and the beta cell: implications for obesity and diabetes. Diabetologia. 57, 1505-1516.
124. Ueno, M., Chiba, Y., Matsumoto, K., Nakagawa, T., Miyanaka, H. (2014). Clearance of beta-amyloid in the brain. Curr. Med. Chem. 21, 4085-4090.
125. van der Kant, R., Goldstein, L.S. (2015). Cellular functions of the amyloid precursor protein from development to dementia. Dev. Cell. 32, 502-515.
126. Vandal, M., White, P.J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., Lefrançois, D., Virgili, J., Planel, E., Giguere, Y., Marette, A., Calon, F. (2014). Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes. 63, 4291-4301.
127. Volkow, N.D., Wang, G.J., Tomasi, D., Baler, R.D. (2013). The addictive dimensionality of obesity. Biol. Psychiatry. 73, 811-818.
128. Wang, G.J., Volkow, N.D., Logan, J., Pappas, N.R., Wong, C.T., Zhu, W., Netusil, N., Fowler, J.S. (2001). Brain dopamine and obesity. Lancet. 357, 354-357.
129. Wang, L., Middleton, C.T., Singh, S., Reddy, A.S., Woys, A.M., Strasfeld, D.B., Marek, P., Raleigh, D.P., de Pablo, J.J., Zanni, M.T., Skinner, J.L. (2011). 2DIR spectroscopy of human amylin fibrils reflects stable β-sheet structure. J Am Chem Soc. 133, 16062-16071.
130. Watve, M., Bodas, A., Diwekar, M. (2014). Altered autonomic inputs as a cause of pancreatic β-cell amyloid. Med. Hypotheses. 82, 49-53.
131. Westermark, G., Arora, M.B., Fox, N., Carroll, R., Chan, S.J., Westermark, P., Steiner, D.F. (1995a). Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol. Med. 1, 542-553.
132. Westermark, G.T., Steiner, D.F., Gebre-Medhin, S., Engström, U., Westermark, P. (2000). Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of Langerhans. Ups. J. Med. Sci. 105, 97-106.
133. Westermark, P., Andersson, A., Westermark, G.T. (2011). Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795-826.
134. Westermark, P., Eizirik, D.L., Pipeleers, D.G., Hellerström, C., Andersson, A. (1995b). Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia. 38, 543-549.
135. Westermark, P., Li, Z.C., Westermark, G.T., Leckström, A., Steiner, D.F. (1996). Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 379, 203-206.
136. Westfall, T.C., Curfman-Falvey, M. (1995). Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors. J. Cardiovasc. Pharmacol. 26, 932-936.
137. Westwell-Roper, C., Dai, D.L., Soukhatcheva, G., Potter, K.J., van Rooijen, N., Ehses, J.A., Verchere, C.B. (2011). IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J. Immunol. 187, 2755-2765.
138. Wickbom, J., Herrington, M.K., Permert, J., Jansson, A., Arnelo, U. (2008). Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy. Regul. Pept. 148, 21-25.
139. Wielinga, P.Y., Alder, B., Lutz, T.A. (2007). The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol. Behav. 91, 212-217.
140. Wielinga, P.Y., Lowenstein, C., Muff, S., Munz, M., Woods, S.C., Lutz, T.A. (2010). Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol. Behav. 101, 45-52, 2010.
141. Winocur, G., Greenwood, C.E. (2005). Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging. 26 Suppl 1, 46-49.
142. Yaffe, K. (2007). Metabolic syndrome and cognitive decline. Curr. Alzheimer Res. 4, 123-126.
143. Yagui, K., Yamaguchi, T., Kanatsuka, A., Shimada, F., Huang, C.I., Tokuyama, Y., et al. (1995). Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur. J.Endocrinol. 132, 487-496.
144. Young, A., Denaro, M. (1998). Roles of amylin in diabetes and in regulation of nutrient load. Nutrition. 14, 524-527.
145. Zhang, S., Liu, H., Chuang, C.L., Li, X., Au, M., Zhang, L., Phillips, A.R., Scott, D.W., Cooper, G.J. (2014). The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet β cells. FASEB J. 28, 5083-5096.
146. Zhang, Z., Liu, X., Morgan, D.A., Kuburas, A., Thedens, D.R., Russo, A.F., Rahmouni, K. (2011). Neuronal receptor activity-modifying protein 1 promotes energy expenditure in mice. Diabetes. 60, 1063-1071.
147. Zhu, H., Wang, X., Wallack, M., Li, H., Carreras, I., Dedeoglu, A., Hur, J.Y., Zheng, H., Li, H., Fine, R., Mwamburi, M., Sun, X., Kowall, N., Stern, R.A., Qiu, W.Q. (2015). Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol. Psychiatry. 20, 252-262.